Industry Overview

Cardiology surgery devices and drugs market was valued at $38.6 billion in 2025 and is projected to reach $56.7 billion by 2035, growing at a CAGR of 4.0% during the forecast Period (2026-2035). The market encompasses medical devices, surgical instruments, and pharmaceutical therapies used to diagnose, treat, and manage cardiovascular diseases. Growth in this market is driven by the rising prevalence of heart conditions, aging populations, and increasing healthcare expenditure globally. Technological advancements in minimally invasive procedures, implantable devices, and novel drugs are enhancing patient outcomes and adoption rates. The market spans segments including cardiology surgery, devices, and drugs, with applications across coronary artery disease, heart failure, arrhythmias, and heart valve disorders.

Market Dynamics

Rising Prevalence of Cardiovascular Diseases (CVDs) and Risk Factors

One of the most significant drivers for the cardiology surgery devices and drugs market is the increasing global burden of cardiovascular diseases, including coronary artery disease, heart failure, arrhythmias, and valvular disorders. CVDs remain a leading cause of mortality globally, with factors such as sedentary lifestyles, unhealthy diets, hypertension, diabetes, and obesity contributing to higher incidence and prevalence rates. This growing patient population directly increases demand for both advanced surgical interventions and pharmacological therapies, expanding the overall market as healthcare systems seek solutions to manage chronic cardiac conditions effectively.

Technological Advancements in Devices and Surgical Procedures

Innovation in cardiac devices and surgical techniques is another major growth driver. Technological progress has led to the development of minimally invasive procedures (e.g., transcatheter valve replacements, leadless pacemakers, advanced stents) and next?generation diagnostic and monitoring systems that improve procedural success rates, patient recovery times, and long?term outcomes. These advancements are not only enhancing clinical capabilities but also encouraging adoption among physicians and patients alike, expanding market opportunities for device manufacturers and supporting demand for associated pharmaceuticals used peri? and post?procedure.

Aging Population and Rising Healthcare Expenditure

Demographic shifts toward an older global population are contributing significantly to market growth. Elderly individuals are at higher risk for cardiac diseases, which drives the necessity for both surgical interventions and chronic drug therapies. Concurrently, rising healthcare expenditure in developed and emerging economies is enabling wider access to sophisticated cardiology care, including cutting?edge devices and innovative drugs. Governments and private healthcare providers are increasingly investing in cardiac care infrastructure, further supporting market expansion as countries prioritize improved outcomes and capacity to treat complex cardiac conditions.

Market Segmentation

• Based on the type, the market is segmented into cardiology surgery, cardiology devices, and cardiology drugs.
• Based on the application, the market is segmented into coronary artery disease, heart failure, arrhythmia, heart valve disorders, and others.
• Based on the end-user, the market is segmented into hospitals, diagnostic centres, and research institutes.

Hospitals Segment to Grow at a Considerable Market Share

The hospitals segment is expected to lead the Global Cardiology Surgery Devices and Drugs Market over the forecast period, driven by several critical factors. Hospitals remain the primary point of care for patients requiring complex cardiac interventions, including open-heart surgeries, minimally invasive procedures, and advanced device implantation such as pacemakers, stents, and defibrillators. These facilities offer the comprehensive infrastructure, specialized surgical teams, and intensive care units necessary to manage high-risk cardiovascular patients, which smaller clinics or ambulatory centers often cannot accommodate.

The rising prevalence of cardiovascular diseases, particularly among aging populations, has intensified hospital-based cardiac treatment demand. Hospitals also benefit from established procurement channels and larger budgets, enabling them to invest in cutting-edge cardiology devices and high-cost pharmacological therapies. Additionally, government and private hospital initiatives to improve cardiac care, including advanced cardiac care centers and heart institutes, are expanding treatment accessibility and enhancing patient outcomes, further consolidating hospitals as the largest end-user segment.

Moreover, hospitals play a central role in post-operative care, chronic disease management, and follow-up treatments, which drives recurring demand for cardiology drugs and devices. Their ability to integrate advanced diagnostic tools, surgical innovations, and ongoing patient monitoring ensures that they remain the dominant segment in terms of both volume and revenue within the global cardiology surgery, devices, and drugs market.

Cardiology Devices: A Key Segment in Market Growth

The cardiology devices segment is expected to be the key growth driver within the global cardiology surgery devices and drugs market over the forecast period. This segment includes advanced implants, monitoring systems, and minimally invasive surgical instruments that are essential for the effective management of cardiovascular diseases. The growth of this segment is primarily driven by the rising prevalence of coronary artery disease, arrhythmias, and heart failure, which increasingly require device-based interventions such as pacemakers, implantable cardioverter-defibrillators (ICDs), stents, and transcatheter heart valves. Technological innovations in device design, including leadless pacemakers, biodegradable stents, and robotic-assisted surgical tools, are further enhancing procedural efficiency, patient safety, and clinical outcomes.

 Additionally, the increasing adoption of remote patient monitoring systems and wearable cardiac devices is expanding the scope of cardiology devices beyond the traditional hospital setting, supporting continuous patient care and early detection of complications. With rising healthcare expenditure, greater patient awareness, and expanding geriatric populations across developed and emerging markets, the cardiology devices segment is poised to capture a substantial share of the overall market, offering both high clinical value and commercial growth opportunities. As healthcare systems increasingly prioritize minimally invasive and technologically advanced cardiac interventions, this segment remains the most attractive for investment and development in the coming decade.

Regional Outlook

The global cardiology surgery devices and drugs market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global cardiology surgery devices and drugs market, holding a major share and serving as the largest regional contributor. This leadership is driven by several factors, including a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and substantial healthcare expenditure. The US has one of the highest incidences of coronary artery disease, heart failure, and arrhythmias, which fuels demand for surgical interventions, innovative cardiac devices, and pharmaceutical therapies. Moreover, the country is a hub for technological innovation, hosting leading manufacturers of pacemakers, implantable cardioverter-defibrillators (ICDs), stents, and minimally invasive surgical instruments, as well as pharmaceutical companies developing novel cardiology drugs. Robust research and development activities, coupled with a favorable regulatory environment and rapid adoption of cutting-edge technologies, further strengthen the market position of the US.

Additionally, high patient awareness, widespread insurance coverage, and government initiatives promoting early diagnosis and preventive cardiac care contribute to sustained growth. The combination of clinical demand, technological leadership, and strong healthcare spending ensures that the US remains the dominant player in the global cardiology surgery devices and drugs market, setting benchmarks for innovation, product adoption, and market dynamic globally. Emerging trends such as remote patient monitoring and telecardiology are also expanding market opportunities in the country.

Market Players Outlook

The major companies operating in the global cardiology surgery devices and drugs market include Abbott Laboratories, Boston Scientific Corp., Johnson & Johnson (J&J) MedTech, and Medtronic plc, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In March 2025, Boston Scientific Corp. acquired SoniVie Ltd., a firm specializing in the investigational TIVUS Intravascular Ultrasound System. This system is designed to address hypertensive disorders through renal artery denervation (RDN), targeting nerves around blood vessels to mitigate sympathetic nervous system overactivity related to hypertension, a major cardiovascular risk factor. The TIVUS system employs ultrasound energy for effective nerve ablation while maintaining blood flow, potentially resulting in faster procedures. SoniVie has reported encouraging pilot trial outcomes and initiated the THRIVE global pivotal trial for the device.
• In October 2024, Boston Scientific Corporation received FDA approval for its navigation-enabled FARAWAVENAV Ablation Catheter, designed for paroxysmal atrial fibrillation treatment, as well as 510(k) clearance for the FARAVIEW Software. These technologies integrate with the FARAPULSE Pulsed Field Ablation (PFA) System and the OPAL HDx Mapping System. The FARAWAVE NAV Ablation Catheter enhances the existing FARAWAVE catheter by incorporating magnetic navigation, allowing cardiac mapping and PFA therapy in one device. The FARAVIEW Software visually assists physicians by showcasing catheter placement and therapy application while tracking pulsed field locations in real-time.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cardiology surgery devices and drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.